Brokerages expect that LeMaitre Vascular, Inc. (NASDAQ:LMAT) will post $26.29 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for LeMaitre Vascular’s earnings, with estimates ranging from $26.00 million to $26.57 million. LeMaitre Vascular posted sales of $23.29 million in the same quarter last year, which suggests a positive year over year growth rate of 12.9%. The company is expected to issue its next earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that LeMaitre Vascular will report full-year sales of $26.29 million for the current financial year, with estimates ranging from $100.70 million to $101.28 million. For the next financial year, analysts expect that the company will post sales of $110.85 million per share, with estimates ranging from $109.90 million to $111.80 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. The company had revenue of $24.80 million during the quarter, compared to the consensus estimate of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period last year, the business posted $0.17 EPS.

Several analysts have recently commented on the company. BidaskClub downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. Canaccord Genuity restated a “hold” rating and issued a $30.00 target price on shares of LeMaitre Vascular in a research note on Monday, October 9th. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, September 28th. First Analysis downgraded LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price for the company. in a research note on Friday, October 27th. Finally, Stifel Nicolaus restated a “buy” rating on shares of LeMaitre Vascular in a research note on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.20.

In other LeMaitre Vascular news, insider David B. Roberts sold 4,123 shares of LeMaitre Vascular stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the completion of the transaction, the insider now owns 24,482 shares in the company, valued at approximately $786,851.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 23.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in LMAT. BNP Paribas Arbitrage SA boosted its stake in shares of LeMaitre Vascular by 11,612.5% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 3,716 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new position in shares of LeMaitre Vascular in the 2nd quarter worth approximately $137,000. Victory Capital Management Inc. boosted its stake in shares of LeMaitre Vascular by 181.2% in the 3rd quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after buying an additional 2,667 shares during the last quarter. Royce & Associates LP purchased a new position in shares of LeMaitre Vascular in the 2nd quarter worth approximately $156,000. Finally, Royal Bank of Canada boosted its stake in shares of LeMaitre Vascular by 856.5% in the 2nd quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 4,505 shares during the last quarter. Hedge funds and other institutional investors own 69.28% of the company’s stock.

Shares of LeMaitre Vascular (NASDAQ LMAT) opened at $31.69 on Friday. The company has a market capitalization of $621.49, a PE ratio of 41.90, a PEG ratio of 2.56 and a beta of 0.55. LeMaitre Vascular has a 12 month low of $19.82 and a 12 month high of $39.88.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 7th. Shareholders of record on Wednesday, November 22nd were paid a dividend of $0.055 per share. The ex-dividend date was Tuesday, November 21st. This represents a $0.22 dividend on an annualized basis and a yield of 0.69%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 28.57%.

WARNING: “LeMaitre Vascular, Inc. (LMAT) Expected to Announce Quarterly Sales of $26.29 Million” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/10/lemaitre-vascular-inc-lmat-expected-to-announce-quarterly-sales-of-26-29-million.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.